These stocks helped lead the market higher. Find out why.
News & Analysis: Alere
Despite a lower price, Abbott's agreement to acquire Alere Inc. gives shareholders a reason to cheer.
Poor Q3 results combined with allegations of submitting claims for deceased patients equals a bad day.
The company is reassuring investors that a new investigation into its billing practices isn't a big deal.
The smoke is beginning to clear, and one Wall Street investment bank likes what it sees.
Offhand comments from Abbott's CEO, and a confusing statement from Alere makes a pending acquisition doubtful.
Less-than-convincing comments from acquirer Abbott Labs are causing a sell-off.
The stock market was lucky to get back to breakeven, but these stocks soared. Find out why.
A disappointing earnings report mixed with lower than hoped for guidance sends shares plummeting.
This is how Alere Connect develops new devices.